Key terms

About CARA

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CARA news

Apr 12 6:16am ET Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment by TipRanks Mar 28 6:00am ET Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA) by TipRanks Mar 27 9:50am ET Cara Therapeutics to host conference call by TipRanks Mar 27 4:55am ET Cara Therapeutics to host conference call by TipRanks Mar 26 5:14pm ET Cara Therapeutics to host conference call by TipRanks Mar 22 4:23pm ET Cara Therapeutics CMO Resigns for New Opportunity by TipRanks Mar 08 1:00am ET Cara Therapeutics Is Worried About This – Should You Be Worried Too? by TipRanks Mar 07 10:29am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 06 11:12am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 06 6:19am ET Cara Therapeutics price target lowered to $10 from $11 at Canaccord by TipRanks Mar 05 5:55am ET Cara Therapeutics: Promising Phase 2/3 Trial Progression Fuels Buy Rating by TipRanks Mar 04 4:09pm ET Cara Therapeutics: Cash and cash equivalents sufficient for operations into 2026 by TipRanks Mar 04 4:07pm ET Cara Therapeutics reports Q4 EPS (59c), consensus (41c) by TipRanks Feb 26 11:01am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 26 11:01am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Jan 23 7:45am ET Strong Buy Recommendation for Cara Therapeutics Based on Promising Notalgia Paresthetica Program and Solid Financial Position by TipRanks Jan 22 3:22pm ET Strategic Restructuring and Focus on NP Program Justify Buy Rating for Cara Therapeutics by TipRanks Jan 22 7:05am ET Cara Therapeutics sees cash runway into 2026 by TipRanks Jan 22 7:04am ET Cara Therapeutics CSO Frederique Menzaghi to depart by TipRanks Jan 22 7:04am ET Cara Therapeutics to discontinue Phase 3 program in advanced CKD by TipRanks Jan 22 7:03am ET Cara Therapeutics announces planned workforce reduction of up to 50% by TipRanks Jan 22 7:02am ET Cara Therapeutics prioritizes late-stage notalgia paresthetic program by TipRanks

No recent press releases are available for CARA

CARA Financials

1-year income & revenue

Key terms

CARA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CARA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching